This randomized controlled clinical trial aims to evaluate the effectiveness of dual-task training on cognitive functions in patients with Alzheimer's disease. Participants will be randomly assigned to either a dual-task training group or a conventional exercise group. The intervention will last 8 weeks, with three supervised sessions per week. Cognitive performance, mobility, balance, and quality of life will be assessed before and after the intervention.
Alzheimer's disease is a progressive neurodegenerative disorder characterized by impairments in memory, executive function, and daily activities. Conventional exercise programs may improve mobility and physical performance, but their impact on cognition is limited. Dual-task training, which integrates motor and cognitive activities simultaneously, has emerged as a promising strategy to enhance neuroplasticity and functional independence in individuals with cognitive decline. In this study, participants diagnosed with Alzheimer's disease according to standard clinical criteria will be recruited. After baseline assessments, participants will be randomly allocated to one of two groups: Experimental Group (Dual-Task Training): Participants will perform exercises combining cognitive tasks (e.g., arithmetic, memory recall, word association) with simultaneous motor tasks (e.g., walking, balance training, functional mobility exercises). Control Group (Conventional Exercise): Participants will engage in standard physical exercises focusing on strength, flexibility, and balance, without added cognitive tasks. The intervention will span 8 weeks, with three 45-60 minute sessions per week, conducted under supervision by a physiotherapist. Outcome Measures Primary Outcomes: Cognitive performance assessed by the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). Secondary Outcomes: Functional mobility (Timed Up and Go test), balance (Berg Balance Scale), and quality of life (QoL-AD questionnaire). Hypothesis It is hypothesized that dual-task training will lead to greater improvements in cognitive performance and functional independence compared to conventional exercise programs. This study may provide evidence supporting dual-task rehabilitation as a complementary approach in the management of Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Participants assigned to this group will undergo dual-task motor-cognitive training, which combines physical exercises with simultaneous cognitive tasks. Sessions will last 45-60 minutes, three times per week, for 8 weeks. Exercises will include gait and balance activities performed while engaging in cognitive tasks such as arithmetic, memory recall, or word association.
Participants in this group will receive a conventional exercise program focusing on strength, flexibility, and balance without a cognitive component. Sessions will last 45-60 minutes, three times per week, for 8 weeks, and will be supervised by a physiotherapist.
d2 Test of Attention
A widely used neuropsychological test evaluating visual attention and processing speed. Participants are asked to quickly and accurately mark target symbols (e.g., the letter "d" with two dashes) among distractors on a sheet consisting of similar letters and symbols.
Time frame: From enrollment to the end of treatment at 8 weeks
Trail Making Test Part A (TMT-A)
Assesses visual attention, processing speed, and psychological flexibility. The participant is required to connect numbered circles from 1 to 25 in order as quickly as possible.
Time frame: From enrollment to the end of treatment at 8 weeks
Stroop Test
Stroop Test: Evaluates executive functions and attentional control. The participant must state the ink color of a word rather than reading the written word itself (e.g., the word "Blue" written in red ink should be answered as "red")
Time frame: From enrollment to the end of treatment at 8 weeks
Trail Making Test Part B (TMT-B):
Trail Making Test Part B (TMT-B): Used to assess executive functions, cognitive flexibility, and attention. The participant alternates between numbers and letters in sequence (1-A-2-B-3-C…)
Time frame: From enrollment to the end of treatment at 8 weeks
Montreal Cognitive Assessment (MoCA)
Montreal Cognitive Assessment (MoCA): Evaluates memory, attention, executive functions, and visuospatial skills. It is a standard and validated tool for monitoring cognitive status and comparing pre- and post-intervention performance in Alzheimer's patients
Time frame: From enrollment to the end of treatment at 8 weeks
Symbol Digit Modalities Test (SDMT)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Symbol Digit Modalities Test (SDMT): Measures processing speed and attention. Participants are presented with a key of symbol-digit pairings and asked to match as many symbols with their corresponding digits as possible within a set time
Time frame: From enrollment to the end of treatment at 8 weeks
Functional Near-Infrared Spectroscopy (fNIRS)
Functional Near-Infrared Spectroscopy (fNIRS): A non-invasive method to measure prefrontal cortex activation by monitoring oxygenated and deoxygenated hemoglobin levels
Time frame: From enrollment to the end of treatment at 8 weeks
Disability Assessment for Dementia (DAD)
Disability Assessment for Dementia (DAD): Developed to assess independence in activities of daily living among individuals with dementia. It evaluates both basic and instrumental activities of daily living, including self-care and social functioning
Time frame: From enrollment to the end of treatment at 8 weeks
Dual Task Protocol
Dual Task Protocol: Participants will perform physical and cognitive tasks simultaneously. For example, during walking, they will be asked to complete word generation, simple arithmetic, or other attention-demanding tasks
Time frame: From enrollment to the end of treatment at 8 weeks
Performance Measures: Walking speed
Walking speed (measured using a metronome or gait analysis system).
Time frame: From enrollment to the end of treatment at 8 weeks
Performance Measures: Step count
Step count (measured using a metronome or gait analysis system).
Time frame: From enrollment to the end of treatment at 8 weeks
Performance Measures: Number of correct response Number of correct responses
Number of correct responses recorded during the secondary cognitive task.
Time frame: From enrollment to the end of treatment at 8 weeks
Performance Measures: incorrect response
Percentage of incorrect responses recorded during the secondary cognitive task.
Time frame: From enrollment to the end of treatment at 8 weeks
Gait Analysis System: Walking speed during single-task walking
Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers.
Time frame: From enrollment to the end of treatment at 8 weeks
Gait Analysis System: Step length during single-task walking
Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers.
Time frame: From enrollment to the end of treatment at 8 weeks
Gait Analysis System:Balance during dual-task walking
Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers.
Time frame: From enrollment to the end of treatment at 8 weeks
Gait Analysis System: Postural control during dual-task walking
Provides objective evaluation of walking dynamics using pressure sensors, motion capture systems, or accelerometers.
Time frame: From enrollment to the end of treatment at 8 weeks
Electromyography (EMG)
Electromyography (EMG): Measures muscle electrical activity through surface electrodes, providing data on contraction duration, activation levels, and coordination (De Luca, 1997). EMG will be used to assess changes in motor control and muscle activation during dual-task training.
Time frame: From enrollment to the end of treatment at 8 weeks